Literature DB >> 17977273

Incidence of symptomatic hemorrhage after stereotactic electrode placement.

Charles A Sansur1, Robert C Frysinger, Nader Pouratian, Kai-Ming Fu, Markus Bittl, Rod J Oskouian, Edward R Laws, W Jeffrey Elias.   

Abstract

OBJECT: Intracranial hemorrhage (ICH) is the most significant complication associated with the placement of stereotactic intracerebral electrodes. Previous reports have suggested that hypertension and the use of microelectrode recording (MER) are risk factors for cerebral hemorrhage. The authors evaluated the incidence of symptomatic ICH in a large cohort of patients with various diseases treated with stereotactic electrode placement. They examined the effect of comorbidities on the risk of ICH and independently assessed the risks associated with age, sex, use of MER, diagnosis, target location, hypertension, and previous use of anticoagulant medications. The authors also evaluated the effect of hemorrhage on length of hospital stay and discharge disposition.
METHODS: Between 1991 and 2005, 567 electrodes were placed by two neurosurgeons during 337 procedures in 259 patients. Deep brain stimulation (DBS) was performed in 167 procedures, radiofrequency lesioning (RFL) of subcortical structures in 74, and depth electrodes were used in 96 procedures in patients with epilepsy. Electrodes were grouped according to target, patient diagnosis, use of MER, patient history of hypertension, and patient prior use of anticoagulant medication (stopped 10 days before surgery). The Charlson Comorbidity Index (CCI) was used to evaluate the effect of comorbidities. The CCI score, patient age, length of hospital stay, and discharge status were continuous variables. Symptomatic hemorrhages were grouped as transient or leading to permanent neurological deficits.
RESULTS: The risk of hemorrhage leading to permanent neurological deficits in this study was 0.7%, and the risk of symptomatic hemorrhage was 1.2%. A patient history of hypertension was the most significant factor associated with hemorrhage (p = 0.007). Older age, male sex, and a diagnosis of Parkinson disease (PD) were also significantly associated with hemorrhage (p = 0.01, 0.04, 0.007, respectively). High CCI scores, specific target locations, and prior use of anticoagulant therapy were not associated with an increased risk of hemorrhage. The use of MER was not found to be correlated with an increased hemorrhage rate (p = 0.34); however, the number of hemorrhages in the patients who underwent DBS was insufficient to draw definitive conclusions. The mean length of stay for the DBS, RFL, and depth electrode patient groups was 2.9, 2.6, and 11.0 days, respectively. For patients who received DBS and RFL, the mean duration of hospitalization in cases of symptomatic hemorrhage was 8.2 days compared with 2.7 days in those without hemorrhaging (p < 0.0001). Three of the seven patients with symptomatic hemorrhages were discharged home.
CONCLUSIONS: The placement of stereotactic electrodes is generally safe, with a symptomatic hemorrhage rate of 1.2%, and a 0.7% rate of permanent neurological deficit. Consistent with prior reports, this study confirms that hypertension is a significant risk factor for hemorrhage. Age, male sex, and diagnosis of PD were also significant risk factors. Patients with symptomatic hemorrhage had longer hospital stays and were less likely to be discharged home.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17977273     DOI: 10.3171/JNS-07/11/0998

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  38 in total

Review 1.  Neuromodulation interventions for addictive disorders: challenges, promise, and roadmap for future research.

Authors:  Primavera A Spagnolo; David Goldman
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

2.  Impact of advancing age on post-operative complications of deep brain stimulation surgery for essential tremor.

Authors:  Terence Verla; Andrew Marky; Harrison Farber; Frank W Petraglia; John Gallis; Yuliya Lokhnygina; Beth Parente; Patrick Hickey; Dennis A Turner; Shivanand P Lad
Journal:  J Clin Neurosci       Date:  2015-02-07       Impact factor: 1.961

3.  Intracranial delivery of stem cells.

Authors:  Keith W Muir; John Sinden; Erik Miljan; Laurence Dunn
Journal:  Transl Stroke Res       Date:  2011-07-26       Impact factor: 6.829

Review 4.  Unusual complications of deep brain stimulation.

Authors:  Fumin Tong; Adolfo Ramirez-Zamora; Lucy Gee; Julie Pilitsis
Journal:  Neurosurg Rev       Date:  2014-10-25       Impact factor: 3.042

5.  Combination of CT angiography and MRI in surgical planning of deep brain stimulation.

Authors:  Marie T Krüger; Volker A Coenen; Carolin Jenkner; Horst Urbach; Karl Egger; Peter C Reinacher
Journal:  Neuroradiology       Date:  2018-08-22       Impact factor: 2.804

6.  Interventional MR Imaging for Deep-Brain Stimulation Electrode Placement.

Authors:  Thanissara Chansakul; Paul N Chen; Thomas C Lee; Travis Tierney
Journal:  Radiology       Date:  2016-06-20       Impact factor: 11.105

7.  Use of intra-operative stimulation of brainstem lesion target sites for frameless stereotactic biopsies.

Authors:  Jason Labuschagne; Denis Mutyaba; Jacques Nel; Claudia Casieri
Journal:  Childs Nerv Syst       Date:  2021-03-08       Impact factor: 1.475

8.  Bilateral Subthalamic Nucleus Deep Brain Stimulation in Elderly Patients With Parkinson Disease: A Case-Control Study.

Authors:  Kyle T Mitchell; John R Younce; Scott A Norris; Samer D Tabbal; Joshua L Dowling; Keith M Rich; Joel S Perlmutter; Mwiza Ushe
Journal:  Oper Neurosurg (Hagerstown)       Date:  2020-09-01       Impact factor: 2.703

9.  Deep brain stimulation in Parkinson's disease: motor effects relative to the MRI-defined STN.

Authors:  Juergen Ralf Schlaier; Christine Hanson; Annette Janzen; Claudia Fellner; Andreas Hochreiter; Martin Proescholdt; Alexander Brawanski; Max Lange
Journal:  Neurosurg Rev       Date:  2014-02-28       Impact factor: 3.042

10.  Deep brain stimulation for the treatment of Parkinson's disease: efficacy and safety.

Authors:  Nader Pouratian; Sandeep Thakkar; Won Kim; Jeff M Bronstein
Journal:  Degener Neurol Neuromuscul Dis       Date:  2012-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.